$0.32
5.81% day before yesterday
Nasdaq, Nov 01, 09:00 pm CET
ISIN
US31572Q8087
Symbol
FGEN
Sector
Industry

FibroGen, Inc. Target price 2024 - Analyst rating & recommendation

FibroGen, Inc. Classifications & Recommendation:

Hold
33%
Sell
67%

FibroGen, Inc. Price Target

Target Price $1.50
Price $0.32
Potential
Number of Estimates 1
1 Analyst has issued a FibroGen, Inc. price target 2025. The average FibroGen, Inc. target price is $1.50. This is higher than the current stock price.
A rating was issued by 3 analysts: 0 Analysts recommend FibroGen, Inc. to buy, 1 to hold and 2 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the FibroGen, Inc. stock has an average upside potential 2025 of . Most analysts recommend the FibroGen, Inc. stock at Sale.

Sales and Margin forecast 2024, 2025 to 2027

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '23 2024
Estimates
Revenue Million $ 147.75 174.43
4.99% 18.06%
EBITDA Margin -175.49% -49.15%
14.96% 71.99%
Net Margin -198.42% -58.77%
11.42% 70.38%

2 Analysts have issued a sales forecast FibroGen, Inc. 2024 . The average FibroGen, Inc. sales estimate is

$174m
Unlock
. This is
0.35% higher
Unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
$177m 2.04%
Unlock
, the lowest is
$171m 1.34%
Unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2023 $148m 4.99%
2024
$174m 18.06%
Unlock
2025
$150m 14.12%
Unlock
2026
$161m 7.55%
Unlock
2027
$213m 32.19%
Unlock

1 Analyst has issued an EBITDA forecast FibroGen, Inc. 2024 . The average FibroGen, Inc. EBITDA estimate is

$-85.7m
Unlock
. This is
39.29% higher
Unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
$-85.7m 39.29%
Unlock
, the lowest is
$-85.7m 39.29%
Unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2023 $-259m 10.72%
2024
$-85.7m 66.94%
Unlock
2025
$-79.6m 7.10%
Unlock
2026
$-73.2m 8.07%
Unlock

EBITDA Margin

2023 -175.49% 14.96%
2024
-49.15% 71.99%
Unlock
2025
-53.17% 8.18%
Unlock
2026
-45.45% 14.52%
Unlock

2 FibroGen, Inc. Analysts have issued a net profit forecast 2024. The average FibroGen, Inc. net profit estimate is

$-103m
Unlock
. This is
40.29% higher
Unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
$-92.4m 46.20%
Unlock
, the lowest is
$-113m 34.38%
Unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2023 $-293m 7.01%
2024
$-103m 65.03%
Unlock
2025
$-69.5m 32.17%
Unlock
2026
$-35.6m 48.84%
Unlock
2027
$94.7m 366.32%
Unlock

Net Margin

2023 -198.42% 11.42%
2024
-58.77% 70.38%
Unlock
2025
-46.41% 21.03%
Unlock
2026
-22.08% 52.42%
Unlock
2027
44.48% 301.45%
Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2024, 2025 to 2027

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '23 2024
Estimates
Earnings Per Share $ -2.92 -1.02
7.01% 65.07%
P/E negative
EV/Sales 0.56

2 Analysts have issued a FibroGen, Inc. forecast for earnings per share. The average FibroGen, Inc. <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is

$-1.02
Unlock
. This is
40.35% higher
Unlock
than earnings per share in the financial year 2023. The highest <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS forecast is
$-0.92 46.20%
Unlock
, the lowest is
$-1.12 34.50%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2023 $-2.92 7.01%
2024
$-1.02 65.07%
Unlock
2025
$-0.69 32.35%
Unlock
2026
$-0.35 49.28%
Unlock
2027
$0.94 368.57%
Unlock

P/E ratio

Current -0.19 35.71%
2024
-0.31 63.16%
Unlock
2025
-0.46 48.39%
Unlock
2026
-0.90 95.65%
Unlock
2027
0.34 137.78%
Unlock

Based on analysts' sales estimates for 2024, the FibroGen, Inc. stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of

and an <a href=https://blog.stocksguide.com/knowledge/price-sales-ratio-simply-explained>P/S ratio of .

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 0.56 200.00%
2024
0.56 0.64%
Unlock
2025
0.65 16.45%
Unlock
2026
0.60 7.02%
Unlock
2027
0.46 24.35%
Unlock

P/S ratio

Current 0.18 48.56%
2024
0.18 0.33%
Unlock
2025
0.21 16.45%
Unlock
2026
0.20 7.06%
Unlock
2027
0.15 24.36%
Unlock

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today